Abstract:Pumilio 1 (PUM1), an RNA binding protein, induces metabolic reprogramming through post‐transcriptional regulation of DEP domain‐containing mammalian TOR (mTOR)‐interacting protein (DEPTOR) in gastric cancer (GC). This study reveals the critical epigenetic role of PUM1 in modulating DEPTOR‐dependent GC glycolytic metabolism, supporting further clinical investigation of PUM1 inhibitors as a metabolic‐targeting strategy for GC. RNA‐binding proteins (RBPs) play essential roles in tumorigenesis and progression, but their functions in gastric cancer (GC) remain largely elusive. Here, it is reported that Pumilio 1 (PUM1), an RBP, induces metabolic reprogramming through post‐transcriptional regulation of DEP domain‐containing mammalian target of rapamycin (mTOR)‐interacting protein (DEPTOR) in GC. In clinical samples, elevated expression of PUM1 is associated with recurrence, metastasis, and poor survival. In vitro and in vivo experiments demonstrate that knockdown of PUM1 inhibits the proliferation and metastasis of GC cells. In addition, RNA‐sequencing and bioinformatics analyses show that PUM1 is enriched in the glycolysis gene signature. Metabolomics studies confirm that PUM1 deficiency suppresses glycolytic metabolism. Mechanistically, PUM1 binds directly to DEPTOR mRNA pumilio response element to maintain the stability of the transcript and prevent DEPTOR degradation through post‐transcriptional pathway. PUM1‐mediated DEPTOR upregulation inhibits mTORC1 and alleviates the inhibitory feedback signal transmitted from mTORC1 to PI3K under normal conditions, thus activating the PI3K–Akt signal and glycolysis continuously. Collectively, these results reveal the critical epigenetic role of PUM1 in modulating DEPTOR‐dependent GC progression. These conclusions support further clinical investigation of PUM1 inhibitors as a metabolic‐targeting treatment strategy for GC.

PUMILIO proteins promote colorectal cancer growth via suppressing p21

PUMILIO Proteins in Colorectal Cancer: Tumor Growth Promoting Function and Potential as Therapeutic Targets

PIM3 Functions As Oncogenic Factor and Promotes the Tumor Growth and Metastasis in Colorectal Cancer

PUM1 Promotes Ovarian Cancer Proliferation, Migration and Invasion

Pumilio1 Regulates NPM3/NPM1 Axis to Promote PD-L1-mediated Immune Escape in Gastric Cancer.

Pumilio 1 suppresses multiple activators of p53 to safeguard spermatogenesis.

Pumilio RNA binding family member 1 deficiency activates anti-tumor immunity in hepatocellular carcinoma via restraining M2 macrophage polarization

PFDN1, an indicator for colorectal cancer prognosis, enhances tumor cell proliferation and motility through cytoskeletal reorganization

Upregulation of CPE promotes cell proliferation and tumorigenicity in colorectal cancer

Depletion of P21-Activated Kinase 1 Up-Regulates the Immune System of APC∆14/+ Mice and Inhibits Intestinal Tumorigenesis

PUM1 Promotes Tumor Progression by Activating DEPTOR‐Meditated Glycolysis in Gastric Cancer

Overexpression of Protein Regulator of Cytokinesis 1 Facilitates Tumor Growth and Indicates Unfavorable Prognosis of Patients with Colon Cancer

Knockdown of circPUM1 impedes cell growth, metastasis and glycolysis of papillary thyroid cancer via enhancing MAPK1 expression by serving as the sponge of miR-21-5p

POFUT1 Promotes Colorectal Cancer Development Through the Activation of Notch1 Signaling.

Targeting Mtor Suppressed Colon Cancer Growth Through 4ebp1/eif4e/puma Pathway

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Chemotherapy mediates intestinal injury via p53/p53 upregulated modulator of apoptosis (PUMA) signaling pathway

Circpum1 Promotes Tumorigenesis and Progression of Ovarian Cancer by Sponging Mir-615-5p and Mir-6753-5p

Pim1 Supports Human Colorectal Cancer Growth During Glucose Deprivation by Enhancing the Warburg Effect.

Prognostic and Immunomodulatory Effects of PIM1 in Colorectal Carcinoma.

UTP18-mediated p21 mRNA instability drives adenoma-carcinoma progression in colorectal cancer